RZLT
Rezolute, Inc.Healthcare·Biotechnology
$3.30
$318M market cap
Revenue
$0.0M
Free Cash Flow
$-73.5M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial fo
2-Year Price History
$3.25-43.2%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q3 | 0.0 | -17.4 | -17.4 | -16.2 | -13.7 | -13.7 | -0.0 | 120.3 | 1.1 | 104.0 | <-999% | -- | -- |
| Act | 2026-Q2 | 0.0 | -24.2 | -24.2 | -22.8 | -20.3 | -20.3 | -0.0 | 132.9 | 1.3 | 103.7 | -524.8% | -- | -- |
| Act | 2026-Q1 | 0.0 | -18.1 | -19.8 | -18.2 | -17.4 | -17.4 | -0.0 | 152.2 | 1.5 | 103.4 | -206.6% | -- | -- |
| Act | 2025-Q4 | 0.0 | -25.8 | -25.9 | -24.4 | -22.0 | -22.0 | -0.0 | 167.9 | 1.6 | 94.3 | -190.4% | -- | -- |
Historical Valuation
Multiples vs the company's own history — cheap or rich relative to itself? Historical fiscal years, then TTM, then forward projections (E). Forward rows hold today's price against projected earnings, so the multiple compresses if the company grows into it.
| Year | Price | Rev Gr | EBITDA % | EBITDA | EV/EBITDA | EV/FCF | P/E | P/S |
|---|---|---|---|---|---|---|---|---|
| TTM | 3.30 | — | — | -86 | 0.0× | 0.0× | 0.0× | — |
EBITDA in reporting-currency $M. Historical multiples use year-end market cap (split-adjusted price history); TTM & forward years use today's.
Valuation & Metrics
Market Stats
Price$3.30
Market Cap$318M
Enterprise Value$199M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-23.1%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-81.5M
Free Cash Flow$-73.5M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-483.6%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares13.7M
Days to Cover9.4
Change (vs Prior)+6.7%
Need at least 2 settlement dates for chart
Employees
Headcount64
Revenue / Employee$0
Gross Profit / Employee$-359
Cash Runway
19.6months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
63.8%(+27.5% YoY)
110 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
17.5%(+13.9% YoY)
9 filers
Vanguard, iShares, SPDR
Market makers
0.8%(-0.2% YoY)
5 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| FEDERATED HERMES, INC. | $39.6M | $2.82 | −$10.8M | +$5.2M | -1.1% | $61.33B |
| RA CAPITAL MANAGEMENT, L.P. | $28.0M | $2.36 | +$0 | +$28.0M | -4.4% | $9.44B |
| BlackRock, Inc.Passive | $19.3M | $4.61 | −$1.4M | +$17.9M | -0.2% | $5.69T |
| Opaleye Management Inc. | $19.2M | $2.69 | +$39K | +$17.8M | +0.9% | $759M |
| BALYASNY ASSET MANAGEMENT LLC | $15.4M | $4.93 | +$1.7M | +$15.3M | -0.4% | $48.01B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $10.7M | $3.05 | +$10.7M | +$10.7M | — | $4.04T |
| JENNISON ASSOCIATES LLC | $10.5M | $3.05 | +$10.5M | +$10.5M | +2.7% | $145.31B |
| Siren, L.L.C. | $10.2M | $9.40 | −$4.7M | +$10.2M | +6.4% | $3.61B |
| VANGUARD PORTFOLIO MANAGEMENT LLCPassive | $9.1M | $3.05 | +$9.1M | +$9.1M | — | $1.91T |
| BANK OF AMERICA CORP /DE/ | $9.1M | $4.23 | −$4.1M | +$7.3M | -0.1% | $1.36T |
| MORGAN STANLEY | $8.4M | $3.19 | +$3.8M | +$7.9M | -0.3% | $1.65T |
| Integral Health Asset Management, LLC | $6.1M | $5.06 | +$0 | +$4.6M | -0.4% | $1.64B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $6.0M | $4.45 | +$29K | +$4.3M | +2.3% | $1.61T |
| UBS Group AG | $5.9M | $4.07 | −$2.7M | +$4.0M | -0.3% | $562.11B |
| STATE STREET CORPPassive | $5.4M | $5.01 | −$6.7M | +$4.8M | -0.2% | $2.89T |
| D. E. Shaw & Co., Inc. | $5.4M | $2.95 | +$4.6M | +$5.4M | -0.3% | $118.02B |
| Affinity Asset Advisors, LLC | $4.7M | $3.06 | −$2.5M | −$465K | +0.5% | $1.60B |
| MILLENNIUM MANAGEMENT LLC | $4.6M | $2.71 | −$590K | +$2.4M | -0.5% | $127.40B |
| KENNEDY CAPITAL MANAGEMENT LLC | $3.8M | $2.83 | +$1.6M | +$3.8M | -1.5% | $4.72B |
| GREAT POINT PARTNERS LLC | $2.9M | $4.44 | +$0 | +$362K | -4.2% | $408M |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-0.54%
avg per quarter
Holders (ex-self)
-0.52%
excl. this stock
Buyers (this Q)
+0.52%
62 buyers · $0.07B in
Sellers (this Q)
+3.12%
45 sellers · $0.08B out
alpha coverage: 92% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-6.0%
how holders react when this stock falls
On quiet Qs
+8.0%
−10% to +10% baseline
On rallies (+10%+)
+22.2%
how they react when this stock rises
Holders' portfolio flow this Q
+2.2%
inflows — adds are organic
Sellers' portfolio flow this Q
-0.4%
Sellers' overall flow ~ flat.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-6.9%
Holder mid (any stock)
-3.8%
Holder rally (any stock)
-7.1%
Biggest decreases this quarter
FEDERATED HERMES, INC.−$10.8Mα-1.1STATE STREET CORP−$6.7Mα-0.2Siren, L.L.C.−$4.7Mα+6.4BANK OF AMERICA CORP /DE/−$4.1Mα-0.1Vestal Point Capital, LPexited−$4.0MUBS Group AG−$2.7Mα-0.3AMERIPRISE FINANCIAL INCexited−$2.6MAffinity Asset Advisors, LLC−$2.5Mα+0.5BlackRock, Inc.−$1.4Mα-0.2SUPERSTRING CAPITAL MANAGEMENT LPexited−$1.2M
New buyers this quarter
Top-5 holders · 46.2%
FEDERATED HERMES, INC.--
RA CAPITAL MANAGEMENT, L.P.--
BlackRock, Inc.--
Opaleye Management Inc.--
BALYASNY ASSET MANAGEMENT LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
FEDERATED HERMES, INC.13.0MFMR LLC57KSiren, L.L.C.3.3MBlackstone Group L.P.—RA CAPITAL MANAGEMENT, L.P.9.2MMANGROVE PARTNERS—MARSHALL WACE, LLP53KUBS Group AG1.9MGREAT POINT PARTNERS LLC952KVivo Capital, LLC—
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (1 analysts)$10.0020300.0%
Last Year (10 analysts)$8.6016060.0%
Current Price$3.30
Analyst Ratings
12
Buy: 12Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$4.33M
11 txns · 7 insiders · 1,384,644 sh
Sells ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-03-30 | BUY | Evans Daron | officer: CFO | 10,000 | $2.85 | $29K | $1.18M |
| 2025-12-16 | BUY | Hogenhuis Wladimir | director | 5,650 | $1.69 | $10K | $202K |
| 2025-12-16 | BUY | ROBERTS BRIAN KENNETH | officer: Chief Medical Officer | 28,000 | $1.70 | $48K | $524K |
| 2025-12-15 | BUY | Elam Nevan C | director, officer: CEO | 32,000 | $1.59 | $51K | $1.02M |
| 2025-12-15 | BUY | Evans Daron | officer: CFO | 45,000 | $1.77 | $80K | $735K |
| 2025-12-15 | BUY | Karnawat Sunil Ratilal | officer: Chief Commercial Officer | 12,100 | $1.62 | $20K | $116K |
| 2025-12-09 | BUY | Evans Daron | officer: CFO | 10,549 | $5.04 | $53K | $665K |
| 2025-06-25 | BUY | ROBERTS BRIAN KENNETH | officer: Chief Medical Officer | 2,500 | $4.38 | $11K | $68K |
| 2025-06-24 | BUY | Evans Daron | officer: CFO | 5,000 | $4.05 | $20K | $1.09M |
| 2025-06-13 | BUY | KREHER NERISSA | director | 3,076 | $3.25 | $10K | $122K |
| 2025-06-13 | BUY | Kim Young-Jin | director | 1,230,769 | $3.25 | $4.00M | $27.38M |
Order Flow (FINRA, ~3w lag)
23.9%retail-1.5pp
14.7%dark+1.4pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Rezolute, Inc.: Clinical failure triggers workforce purge and highlights heavy warrant overhang
Overall Risk
7/10
Fraud
3/10
Dilution
9/10
Insolvency
4/10
Earnings Overstated
2/10
Hidden Liabilities
6/10
Legal
5/10
Audit Warnings
3/10
Hidden Upside
4/10
Contextually Acceptable
6/10